Abstract
Over the last few decades, a number of studies have shown correlations between arterial hypertension (AH) and the risk of development of malignant neoplasms. A literature review has revealed some associations between the factors involved in AH pathogenesis and malignant growth in kidneys. The effect of the components of the renin-angiotensin-aldosterone system (RAAS) on pathological neoangiogenesis, proliferation and apoptosis has been noted. Treatment of patients with RAAS inhibitors reduces the cancer progression and improves the survival of patients with primary and metastatic kidney cancer. It allows us to assume the pathogenetic significance of the RAAS links for the kidney cancer development and progression. In this regard, the possibility of clinical use of ACE inhibitors and/ or ARBs for cancer patients, including those without arterial hypertension, is being discussed, which opens the prospect of studying their potentially new applications in modern pharmacotherapy not only of hypertension but also of malignant diseases.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
